January 31, 2015     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S.

Tokyo, Oct 10, 2013 (JCN) - Dainippon Sumitomo Pharma Co., Ltd. (DSP) announced that it has decided to establish an anti-cancer drugs sales company in the United States as a wholly-owned subsidiary of DSP's 100% owned U.S. holding company.

DSP is conducting a Phase III global clinical study of the anti-cancer drug BBI608 that was created by its U.S. subsidiary Boston Biomedical, Inc. ("BBI"). In this connection, DSP has considered various options for the eventual sales scheme and the organizational structure in preparation for successful conclusion of the BBI608 development.

The sales and marketing activity of anti-cancer drugs requires extraordinary professional expertise, and accordingly DSP is setting up a sales scheme and organizational structure exclusively dedicated to anti-cancer drugs by establishing a new company independent from our existing U.S. subsidiaries.

The new sales subsidiary will be established so that necessary preparations for BBI608 launch can be made in line with the progress of its development. Upon establishment, the new company will start making preparations in anticipation of eventual market launch of BBI608.

The development of BBI608 is underway, with a target launch date in fiscal 2015. BBI608 is an orally-administered first-in-class anti-cancer drug created and currently under development by Boston Biomedical Inc. and was shown to inhibit the Stat3 pathways, Nanog pathways and beta-catenin pathways in pre-clinical study.

BBI608 is a small-molecule compound with a novel mechanism that blocks cancer stem cell (cancer cell with stem cell-like properties) self-renewal and induces cell death in CSC as well as other heterogeneous cancer cells.

By targeting cancer stem cells in addition to heterogeneous cancer cells, efficacy is expected in the current challenges in therapy against cancer, such as treatment resistance, metastasis and recurrence.

By Jun Ota Staff Writer

Copyright © 2015 JCN. All rights reserved. A division of Japan Corporate News Network KK.

 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Dainippon Sumitomo News  
  Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S.  (Oct 10, 2013)
  Dainippon Sumitomo Pharma Opens Subsidiary in Singapore  (Jan 22, 2013)
  Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent  (Dec 28, 2012)
  NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area  (Oct 23, 2008)
  Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug  (May 8, 2008)
  Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic  (Dec 13, 2006)
  Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent  (Nov 28, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs  (July 26, 2006)

 Recent  Drugs & OTC News   
Otsuka Announces Termination of Contracts (Jan 8, 2015)
Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)

More Drugs & OTC news...
CSR Report Download
Annual Reports

  More >>    
Most Popular

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)